Angiotensin II Type 1 Receptor (AGTR1) Human shRNA Plasmid Kit (Locus ID 185)

Specifications

Product Data
Product Name	Angiotensin II Type 1 Receptor (AGTR1) Human shRNA Plasmid Kit (Locus ID 185)
Locus ID	185
UniProt ID	P30556
Synonyms	AG2S; AGTR1B; AT1; AT1AR; AT1B; AT1BR; AT1R; AT2R1; HAT1R
Vector	pRS
Format	Retroviral plasmids
Kit Components	AGTR1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 185). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq	NM_000685, NM_004835, NM_009585, NM_031850, NM_032049, NM_009585.1, NM_009585.2, NM_009585.3, NM_004835.2, NM_004835.3, NM_004835.4, NM_000685.1, NM_000685.2, NM_000685.3, NM_000685.4, NM_031850.1, NM_031850.2, NM_031850.3, NM_032049.1, NM_032049.2, NM_032049.3, BC022447, BC022447.1, BC068494, BC068494.1, NM_009585.4
Summary	Angiotensin II is a potent vasopressor hormone and a primary regulator of aldosterone secretion. It is an important effector controlling blood pressure and volume in the cardiovascular system. It acts through at least two types of receptors. This gene encodes the type 1 receptor which is thought to mediate the major cardiovascular effects of angiotensin II. This gene may play a role in the generation of reperfusion arrhythmias following restoration of blood flow to ischemic or infarcted myocardium. It was previously thought that a related gene, denoted as AGTR1B, existed; however, it is now believed that there is only one type 1 receptor gene in humans. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Aug 2020]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.